LYCOS RETRIEVER 
Disease: Companys
built 275 days ago
ANN ARBOR, Mich., Jan. 28 /PRNewswire/ -- Velcura Therapeutics Inc., an early stage biotechnology company developing therapies for bone disease, recently completed a successful Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA). The IND enables Velcura to proceed with the first-in-man clinical trials for its lead compound, VEL-0230.
Source:
This presentation will include the first data from the Company demonstrating the reduction of globotriaosylceramide (GL-3), the lipid substrate that accumulates in Fabry disease, after oral administration of a pharmacological chaperone. These data were not available at the time of abstract submission but will be included in the presentation at the meeting.
Source:
Pharmacyclics is a pharmaceutical company developing products to improve upon current therapeutic approaches to cancer, atherosclerosis and retinal disease. The company's products are ring-shaped small molecules called texaphyrins. These patented agents are derived from Pharmacyclics' versatile technology platform for designing and synthesizing energy-potentiating drugs. The texaphyrins localize in cancer cells, atherosclerotic plaque and neovasculature, where they can be activated by various forms of energy, including X-rays, light and chemotherapeutics, to reduce or eliminate diseased tissue.
Source:
MORE ABOUT
Companys